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Nasopharyngeal carcinoma (NPC) is a unique cancer. It is a
tumour of epidermoid origin with an endemic distribution among
well-defined ethnic groups, present in several world regions.
Southeastern China and Taiwan have the highest incidence (10–80
per 100 000 persons per year), followed by North Africa, the
Philippines, and the Caribbean nations, but the tumour is rare in
Caucasians (Yu, 1991; Fandi and Cvitkovic, 1994; 1995). NPC
occurs more frequently in males, at a rate approximately 3-fold
that in females (Fandi and Cvitkovic, 1995; 1994). Aside from the
striking racial predilection of the disease, other factors implicated
in the development of NPC are the Epstein-Barr virus (EBV),
genetic and environmental factors. EBV DNA is present in almost
every NPC specimen, and the number of EBV genomic copies is
proportional to the degree of histological differentiation
(Liebowitz, 1994). However, there is compelling evidence
showing that the virus causes a subclinical infection early in life,
resulting in over 90% seropositivity of susceptible individuals by 3
years-of-age in the Far East. These facts indicate that EBV may be
an essential but not a complete factor for the development of NPC
(Choi et al, 1993). The fact that populations in southeastern China
and Taiwan are preferentially affected by NPC suggests a genetic
predisposition for the disease. Several studies of genetic systems
and karyotypes have reported that HLA-2 and HLA-BS, as well as
the deletion of chromosomes at the region of 3p14–21, 3p25 and
9p21–25, are often associated with NPC (Lu et al, 1990; Huang et
al, 1991; 1994). Although these studies have suggested possible
sources of carcinogenesis, little is known about the malignant
progression of NPC. Clinically, NPC is a malignancy that is diffi-
cult to detect in the very early stage, because there are minimal
symptoms and little discomfort at that point. The prognosis is very
good if the cancer is diagnosed and treated in the early stages
(Chang et al, 1996). However, by the time the disease is sympto-
matically apparent, it has often progressed to late stage. As with all
cancers, the best way to improve patient survival is early detec-
tion. A better understanding of the carcinogenesis of NPC may
result in the discovery of a diagnostic marker that would allow
early detection and management, and thus a better prognosis.
Telomerase is a specialized reverse transcriptase that direct the
synthesis of telomeric DNA onto chromosomal ends using a
segment of its integral RNA component as a template (Blackburn,
1992). In most human somatic cells, telomerase activity is unde-
tectable and telomeric length is progressively shortened during
cell proliferation. Cell senescence is thought to occur when the
telomeric length is shortened to a critical point (Campisi, 1997;
Morin, 1997). Conversely, immortalized human cells exhibit stabi-
lized telomeric lengths and are positive for telomerase activity
(Morin, 1997; Wright et al, 1996). Accumulating evidence indi-
cates that telomerase activity is frequently detectable in primary
tumour specimens from malignancies of diverse tissue origins,
less frequently in premalignant and benign proliferative tissues,
and rarely or not at all in normal somatic tissues (Shay and
Bacchetti, 1997). Apparently, activation of telomerase expression
plays an important role during carcinogenesis.
We designed this study to investigate telomerase activity in
diseased nasopharyngeal tissues, including hyperplastic, metaplastic
and malignant tissues. Hyperplasia indicates that cells are prolifer-
ating rapidly, while metaplasia indicates that normal differentiated
cells are replaced by other differentiated cell types. Both hyperplasia
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(Feng and Liu, 1991; Kristensen et al, 1989; Zong and Zheng 1989;
Kieserman and Stern, 1995). The aims of this study were to investi-
gate the level of telomerase activity in different types of nasopha-
ryngeal diseased tissues, and to correlate the levels of telomerase
activity with clinicopathological variables in carcinomas.
MATERIALS AND METHODS
Patients, tissues and cells
Biopsies from 54 consecutive patients visiting Otorhinolaryngology
or Head and Neck Surgery clinics at Chang Gung Memorial
Hospital (Taoyuan, Taiwan) were obtained for study. Written
informed consent was obtained from all patients participating in the
study. One part of each tissue was examined histopathologically, and
the rest was stored in liquid nitrogen until use for telomerase activity
assay. All cancers were histologically graded according to the World
Health Organization (WHO) classification (Hedinger et al, 1989).
For each tissue, the presence of lymphocytes, germinal centres,
mucus cells, vessel hyperplasia or metaplasia, was specifically
recorded. Samples included 17 with inflammation or hyperplasia,
eight with squamous metaplasia and 29 with different stages of
carcinomas. Immature squamous metaplasia represents the morpho-
logic epithelial changes from a single or multiple layers of reserve
cells to an epithelium composed of three or more layers of cells with
features of mature nonkeratinizing squamous epithelial cells
(Yeldandi et al, 1996). Tumour staging was classified by the UICC
system (Hermanek et al, 1997). Nasopharyngeal cancer-derived cell
line NPC076 (Ku et al, 1997), which was used as positive control in
the present study, was kindly provided by Dr I Chang from the
department of microbiology and immunology in our institute.
NPC076 cells were grown at 37°C, 5% CO2 in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine serum and
antibiotics (100 U ml–1 penicillin, 100 U ml–1 streptomycin and 0.25
mg ml–1 amphotericin B).
Extraction of cellular proteins
Telomerase activity of tissue samples was assayed blindly with a
code number and the results were decoded later. Tissue samples
(~50 mg) were homogenized in 300 ml of a lysis buffer (10 mM
Tris-HCI, pH 7.5, 1 mM MgCl2, 1 mM EGTA, 0.5% CHAPS
(Pharmacia), 10% glycerol, 5 mM mercaptoethanol and 0.1 mM
phenylmethylsulfonyl fluoride (PMSF)) in Kontes tubes with
matching pestles rotated at 450 rpm. For control cells of NPC076
protein extraction, the number of cells was counted by hemocy-
tometer and resuspended at 3000 cells ml–1 of the lysis buffer. After
30 min at 4°C, the lysate was centrifuged at 15 000 rpm for 30 min
at 4°C. The supernatants of tissue and NPC cell extracts were
transferred and prepared for telomerase activity assay. The super-
natant of NPC cells was diluted serially to obtain 300, 30 and 3
cells ml–1, respectively. The protein concentration of each tissue
sample was determined using Coomassie protein assay reagent
(Pierce).
Telomerase activity assay
Telomerase activity was assayed by the modified telomeric repeat
amplification protocol (TRAP) (Cheng et al, 1997; 1999). At a
proper buffered condition, the telomeric repeats were synthesized
in the presence of TS primer and enzyme telomerase, which was
present in the cellular protein extract. Telomere products were
subsequently amplified by PCR reaction in the presence of reverse
CX primer. Briefly, 0.3 mg of extract protein was added to a 30 ml
reaction mixture containing 0.1 mg [g-32P]-labelled TS primer
(Genasia Scientific Inc, Taipei, Taiwan), 0.1 mg CX primer
(Genasia Scientific Inc, Taipei, Taiwan), 2 units of Taq DNA poly-
merase (HT Biotech Ltd, Taipei, Taiwan), 20 mM Tris-HCl (pH
8.3), 1.5 mM MgCl2, 63 mM KCl, 0.005% Tween-20, 1 mM
EGTA, 50 mM dNTPs, and 0.1 mg ml–1 bovine serum albumin.
The reaction mixture was incubated at 24°C for 15 min following
PCR amplification of 30 cycles of 94°C for 30 s, 55°C for 30 s,
and 72°C for 1 min in a DNA Thermal Cycler (Perkin Elmer
Cetus, Norwalk, CT, USA). RNase digestion was performed as a
control to confirm that the activity was that of telomerase. For
these reactions, cell extracts were preincubated with 200 mg ml–1
of RNase A (Boehringer Mannheim, Germany) at room tempera-
ture for 20 min before being added to the reaction mixture. The
PCR products were resolved by electrophoresis on a nondena-
turing 10% polyacrylamide gel (PAGE) in a buffer containing 54
mM Tris-HCl, pH 8.0, 54 mM boric acid, 1 mM EDTA. Positive
telomerase activity in an extract is determined by the presence of
six-nucleotide ladder of TRAP products in PAGE which are sensi-
tive to RNase A treatment.
Determining the level of telomerase activity
The autoradiograms of TRAP products on PAGE were quantitated
by computerized scanning densitometry using ImageQuan
(Molecular Dynamics, CA, USA) (Cheng et al, 1997). Relative
levels of telomerase activity were measured by comparing the
intensity of the ladder signals with serial dilution of the NPC076
cell line (3, 30 and 300 cells). Tissues with telomerase activity
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Figure 1 Levels of telomerase activity in different nasopharyngeal tissues.
Protein extracts from 3, 30, or 300 NPC076 cells were used as positive
controls. Levels of telomerase activity from samples A, B, and C were
compared with those of NPC076 cells, as described in the Materials and
methods section. In sample A, level of telomerase activity was greater 300
NPC076 cells, and was considered as strong-positive. In sample B, level of
telomerase activity was between 3 and 30 NPC076 cells, and was
considered as weak-positive. In sample C, telomerase activity was less than
3 NPC076 cells and was considered as negative. Sample N was negative
control, which included all assay components except protein extract.equivalent to less than three NPC076 cells were scored as ‘unde-
tectable’ or ‘negative’. Tissues with telomerase activity equivalent
to 3–30 cells were scored ‘low levels’, while tissues with telom-
erase activity equivalent to 30–300 or greater than 300 NPC076
cells were scored as ‘moderate’ or ‘high level’, respectively.
Examples of the results are shown in Figure 1.
Statistical analysis
For statistical analysis, we divided all samples into three groups:
inflammation or lymphoid hyperplasia (without metaplasia or
carcinoma), squamous metaplasia (without carcinoma), and carci-
noma tissues, according to the degree of pathological transforma-
tion. To examine how telomerase activity varied in different
factors, Fisher’s exact test was used due to small number of
subjects studied. These factors included pathological findings
(inflammation or hyperplasia, squamous metaplasia, carcinomas),
presence or absence of hyperplasia (germinal centre, vessel,
lymphoid, mucus cells), and tumour staging (T and N). All 
P-values were tow-sided. Statical significance was considered if 
P ≤ 0.05. SAS/win 6.12 was used.
RESULTS
Telomerase activity in nasopharyngeal tissues
Examples of the results are shown in Figure 1. Each patient’s
conditions including histological examination data and the level of
telomerase activity are shown on Table 1. Summary of the diag-
nosis is listed in Table 2. Positive telomerase activity was detected
in 1 of 17 (5.9%) inflammatory or hyperplasia tissues, 3 of 8
(37.5%) samples with squamous metaplasia, and 25 of 29 (86.2%)
carcinomas. Telomerase activity in these three groups was signifi-
cantly different (P < 0.001), indicating that telomerase activity
was strongly correlated with the degree of cellular transformation
in nasopharyngeal tissues. For each tissue sample, the degree of
telomerase activity was examined for correlation with commonly
found pathological features, such as germinal centre hyperplasia,
vessel hyperplasia, lymphoid hyperplasia, mucus cell hyperplasia,
and metaplasia. Results are summarized in Table 3. There was no
significant correlation of telomerase activity with any of the above
hyperplastic features. However, telomerase activity was signifi-
cantly associated with the presence of squamous metaplasia 
(P < 0.001).
Telomerase activity in nasopharyngeal cancers
The clinicopathological variables and the level of telomerase
activity from 29 NPC patients were further analysed. The correla-
tion of telomerase activity with primary tumour stage or lymph
node status is summarized in Table 4. Relative level of telomerase
activity was determined by comparison with the activity of control
cells (Materials and methods). Of the 29 carcinomas, four samples
had no detectable telomerase activity, nine samples had a low
level, ten a moderate level, and six a high level of telomerase
activity. For the four NPC patients without detectable telomerase
activity, two had T4 lesion, one had a T3 and one a T2 lesion
(Table 1). Low levels of telomerase activity occurred mostly (8/9)
in lower stages (T1–2) of NPC, and high levels mostly (5/6) in
advanced stages (T3–4) (Table 4). We also found that telomerase
activity was associated with tumor T stage (P = 0.024) but not with
the status of neck lymph node metastatic (P = 0.292) (Table 4).
DISCUSSION
Investigation of various tumours indicates that reactivation of
telomerase activity may occur at different stages depending on the
types of cancers. For example, reactivation of telomerase activity
was found in benign or precancerous tissues of the breast (Sugino
et al, 1996), liver (Tahara et al, 1995), head and neck (Mutirangura
et al, 1996; Califano et al, 1996; Mao et al, 1996), thyroid gland
(Cheng A-J et al, 1998) and colorectum (Tang et al, 1998).
Moreover, some infective tissues were also found positive for
telomerase activity (Tahara et al, 1995; Kameshima et al, 1999). In
studies of prostate and gastric cancers, however, telomerase
activity was only detected in malignant tissues (Hiyama et al,
1997; 1995). These results indicate that reactivation of telomerase
activity during the development of cancers may occur at distinct
carcinogenic steps, depending on the specific type of tissue
involved. In our study, telomerase activity was not only found in
carcinomas but also in some metaplastic tissues and a small
percentage of inflammatory and hyperplastic tissues, suggesting
the enzyme reactivation in NPC may occur at a pre-cancerous
stage of carcinogenesis.
Cellular proliferation and transformation are different aspects of
carcinogenesis, but both are required for malignant formation.
Reports on the roles of telomerase activation with respect to these
two processes are different in various types of cancers. For
example, telomerase activity was correlated with a poorer grade of
cellular differentiation but not with tumour size in liver cancer
(Tahara et al, 1995), indicating that telomerase may be more
involved in cellular transformation. On the other hand, telomerase
activity has been found in mitotically active or regenerating
somatic cells (Ramirez et al, 1997; Herle-Bachor et al, 1996; Kyo
et al, 1997), suggesting that it is associated with cellular prolifera-
tion. Recently, studies in cell-line models further support the
contention that telomerase expression is associated with cellular
immortalization but not with transformation (Morales et al, 1999;
Jiang et al, 1999). In this present study, we did not find a signifi-
cant association of telomerase activity with hyperplasia per se in
nasopharyngeal tissue, but rather with metaplastic change. The
reason for this is unclear. However, all of the above indicate that
telomerase may involve in multiple physiological and pathological
functions.
Recently a number of laboratories have identified a putative
telomerase repressor gene mapped to chromosome region
3p14–21 or 3p21–22 (Mehle et al, 1998; Cuthbert et al, 1999;
Tanaka et al, 1998; Horikawa et al, 1998). For example, loss of
heterozygosity at chromosome 3p correlated with telomerase
activity in renal cell carcinoma (Mehle et al, 1998). Strong repres-
sion of telomerase was observed following transfer of chromo-
some 3 into breast cancer cells (Cuthbert et al, 1999). In
nasopharyngeal cancer patients, loss of heterozygosity or homozy-
gous deletion at the chromosome region of 3p14–21 was often
found (Huang et al, 1994; 1995). Although the association of
telomerase reactivation and chromosome deletion at 3p in NPC
patients was not clear, with such coincidence of these two it may
be postulated that deletion of the chromosome 3p may reactivate
telomerase activity leading to acceleration of malignant transfor-
mation of nasopharyngeal lesions.
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been reported previously (Cheng RYS et al, 1998). Basically, we
agree with previous findings that most malignant nasopharyngeal
tissues are positive for telomerase activity. In this present study,
we extend their observation to non-cancerous nasopharyngeal
lesions by evaluating the enzyme activity in hyperplastic and
metaplastic nasopharyngeal tissues. Percentages of the enzyme
activity were found to increase from hyperplastic through meta-
plastic to malignant tissues. For the telomerase-positive lymphoid
hyperplasia patient (patient 17), other pathological features such as
mucus hyperplasia and sinusitis were also found. In this case, there
is insufficient data to make any assumption about the mechanism
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Table 1 Pathohistological characteristics and telomerase activity of the NPC patients
Tumour stage Histological examination2
Patient1 Diagnosis Telomeras1 T N M Ca Metapl Gem Hp Lym Hp Mucus Vel Hp Sinus
1 inflam/hyp 0 0 0 0 0 0 0 0
2 inflam/hyp 0 0 0 0 0 0 0 0
3 inflam/hyp 0 0 0 0 0 0 0 0
4 inflam/hyp 0 0 0 0 1 1 0 0
5 inflam/hyp 0 0 0 0 1 0 0 0
6 inflam/hyp 0 0 0 0 0 0 0 0
7 inflam/hyp 0 0 0 1 1 0 0 0
8 inflam/hyp 0 0 0 0 0 0 0 0
9 inflam/hyp 0 0 0 0 0 0 0 0
10 inflam/hyp 0 0 0 0 1 1 0 0
11 inflam/hyp 0 0 0 0 0 0 0 0
12 inflam/hyp 0 0 0 1 0 0 0 0
13 inflam/hyp 0 0 0 0 1 1 0 0
14 inflam/hyp 0 0 0 1 0 0 0 0
15 inflam/hyp 0 0 0 0 1 1 0 0
16 inflam/hyp 0 0 0 0 0 0 0 0
17 inflam/hyp 2 0 0 0 1 1 0 1
18 metaplasia 0 0 1 0 1 0 0 0
19 metaplasia 0 0 1 0 1 0 0 0
20 metaplasia 0 0 1 1 1 0 1 0
21 metaplasia 0 0 1 1 1 1 0 0
22 metaplasia 0 0 1 0 1 0 0 0
23 metaplasia 1 0 1 1 0 1 0 0
24 metaplasia 1 0 1 1 1 0 0 0
25 metaplasia 3 0 1 0 1 1 1 0
26 cancerous 0 2 2 0 1 0 0 1 0 0 0
27 cancerous 0 3 0 0 1 0 0 1 0 0 0
28 cancerous 0 4 0 0 1 0 0 1 0 0 0
29 cancerous 0 4 2 0 1 1 1 1 1 0 0
30 cancerous 1 1 1 0 1 1 1 1 0 0 0
31 cancerous 1 2 0 0 1 0 0 1 0 0 0
32 cancerous 1 1 1 0 1 0 0 1 0 0 0
33 cancerous 1 1 0 0 1 1 0 1 0 1 0
34 cancerous 1 1 1 0 1 1 0 1 0 0 0
35 cancerous 1 2 1 0 1 1 1 0 0 0 0
36 cancerous 1 2 0 0 1 1 1 1 0 0 0
37 cancerous 1 4 3 0 1 1 1 1 1 1 0
38 cancerous 1 1 1 0 1 1 0 1 1 0 0
39 cancerous 2 3 1 0 1 1 1 1 0 0 0
40 cancerous 2 2 3 0 1 1 1 1 1 0 0
41 cancerous 2 2 1 0 1 0 0 1 0 0 0
42 cancerous 2 1 1 0 1 0 0 1 0 0 0
43 cancerous 2 2 2 0 1 0 0 1 0 1 0
44 cancerous 2 3 1 1 1 1 0 0 1 0 0
45 cancerous 2 2 0 0 1 1 0 0 0 0 0
46 cancerous 2 4 3 0 1 0 0 1 0 0 0
47 cancerous 2 3 3 0 1 0 1 0 0 0 0
48 cancerous 2 1 1 0 1 0 0 1 0 0 0
49 cancerous 3 1 1 0 1 1 1 0 0 0 0
50 cancerous 3 4 2 0 1 0 0 1 0 0 0
51 cancerous 3 4 2 0 1 1 1 1 1 0 0
52 cancerous 3 3 0 0 1 1 0 1 0 0 0
53 cancerous 3 4 2 0 1 0 0 1 1 1 1
54 cancerous 3 4 1 0 1 0 0 1 0 0 0
1 Telomerase activity was determined as negative (0), low (1), moderate (2), and high (3) levels; 2histological examinations for cancer (Ca), metaplasia
(Metapl), germinal centre hyperplasia (Gem Hp), lymphoid hyperplasia (Lym Hp), mucous cell hyperplasia (Mucus), vessel hyperplasia (Vel Hp) and
sinus were indicated as either presence (1) or absence (0)of telomerase reactivation. Whether the other pathological feature
or a combination of factors contributed to the reactivation of
telomerase is being addressed. For the patients with telomerase-
positive metaplastia, follow-up studies are being conducted to
investigate whether the presence of telomerase activity may corre-
late with further malignant change. Although the relationship
between squamous metaplasia and carcinomatous change in
nasopharyngeal tissue is still unknown, the expression of telom-
erase activity in a subset of the patients with metaplasia may
provide additional clues for us to examine. In carcinoma patients,
detection of higher levels of telomerase activity in the majority of
advance-staged disease (T3–T4) as compared to the early stages
(T1–T2) (P = 0.024) suggests a positive association of telomerase
activity with tumour progression. Prospective investigation of this
question is underway, especially to evaluate whether telomerase
activity correlates with cancer prognosis.
In view of the high frequency of telomerase activity in malig-
nant tissues and in a subset of metaplastic tissues, telomerase may
potentially be used for monitoring the pre-malignant change of
nasopharyngeal lesions. Currently, the diagnosis rests on
histopathological examination, as there is no useful molecular
marker for detecting NPC. Serological anti-EBV antibodies
provide only limited information, because over 90% of the Far
East population have subclinical infections in early childhood, and
are therefore seropositive. In conclusion, the present study
suggests that telomerase activation may play a role in the develop-
ment of nasopharyngeal cancer. Since telomerase activity is found
in the majority of nasopharyngeal cancers and a subset of meta-
plasia, this enzyme may be served as a reference to monitoring the
status of abnormal nasopharyngeal tissues.
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